摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1S,3aR,7S,9aS,9bR)-1-methyl-7-((2S,4S)-4-methyl-5-oxotetrahydrofuran-2-yl)decahydro-3-oxa-6a-azacyclopenta[e]azulen-2-one | 27498-90-4

中文名称
——
中文别名
——
英文名称
(1S,3aR,7S,9aS,9bR)-1-methyl-7-((2S,4S)-4-methyl-5-oxotetrahydrofuran-2-yl)decahydro-3-oxa-6a-azacyclopenta[e]azulen-2-one
英文别名
(-)-stemonine;stemonine;(3aR)-1t-methyl-8t-((2S)-4c-methyl-5-oxo-tetrahydro-furan-2r-yl)-(3ar,10at,10bt)-decahydro-furo[3,2-c]pyrrolo[1,2-a]azepin-2-one;Stemonin;stemonine-C17;(1S,2R,3S,6R,11S)-3-methyl-11-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.02,6]tridecan-4-one
(1S,3aR,7S,9aS,9bR)-1-methyl-7-((2S,4S)-4-methyl-5-oxotetrahydrofuran-2-yl)decahydro-3-oxa-6a-azacyclopenta[e]azulen-2-one化学式
CAS
27498-90-4
化学式
C17H25NO4
mdl
——
分子量
307.39
InChiKey
HTLBMAZNGBFLEY-FICWEOCZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    22
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    55.8
  • 氢给体数:
    0
  • 氢受体数:
    5

SDS

SDS:27ae3c69728a798df9db17f5d6de65b1
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Stemoamide 型生物碱(包括全取代丁烯内酯和吡咯)的全合成及抗炎活性
    摘要:
    包括两个四取代烯烃的完全取代的丁烯内酯是百部生物碱中独特的结构基序,但其合成的有效方法尚未得到很好的发展。作为一项针对茎酰胺基团的集体全合成的正在进行的计划,我们报告了一种立体发散方法,可以从同一中间体中得到 ( E )- 或 ( Z )-全取代的丁烯内酯。虽然通过 E1 型机制 AgOTf 介导的消除导致形成动力学 ( Z )-四取代烯烃,但随后 TfOH 介导的异构化产生热力学 ( E )-四取代烯烃。吡咯环是在Stemona中发现的另一个重要结构生物碱。用MnO 2直接氧化吡咯烷环并仔细纯化得到吡咯基团,而内酯基团中的立体中心没有异构化。这两种方法使我们能够合成一系列干酰胺类生物碱,包括三环、四环和五环框架。通过抑制巨噬细胞系 RAW264.7 中 iNOS 表达的抗炎活性表明,没有细胞毒性的最有效的抗炎化合物是原甾体素,其由包括完全取代的丁烯内酯在内的五环框架组成。
    DOI:
    10.1055/a-1941-8680
  • 作为产物:
    描述:
    (3S,5S)-5-((1S,3aR,7S,9aS,9bR)-2-Hydroxy-1-methyl-decahydro-3-oxa-6a-aza-cyclopenta[e]azulen-7-yl)-3-methyl-dihydro-furan-2-one 在 chromium(VI) oxide硫酸 作用下, 以 四氢呋喃丙酮 为溶剂, 以68%的产率得到(1S,3aR,7S,9aS,9bR)-1-methyl-7-((2S,4S)-4-methyl-5-oxotetrahydrofuran-2-yl)decahydro-3-oxa-6a-azacyclopenta[e]azulen-2-one
    参考文献:
    名称:
    (-)-stemonine的总合成。
    摘要:
    [反应:见正文]通过无环前体2的会聚组装,报道了对-(-)-stemonine(1)的对映选择性全合成。关键的转化包括Staudinger-aza-Wittig反应形成中央全氢氮杂多环体系和碘诱导的串联环化反应,以构建吡咯烷基-丁内酯框架。
    DOI:
    10.1021/ol035368q
点击查看最新优质反应信息

文献信息

  • Lactam Strategy Using Amide-Selective Nucleophilic Addition for Quick Access to Complex Amines: Unified Total Synthesis of Stemoamide-Type Alkaloids
    作者:Yasukazu Sugiyama、Yasuki Soda、Makoto Yoritate、Hayato Tajima、Yoshito Takahashi、Kana Shibuya、Chisato Ogihara、Takashi Yokoyama、Takeshi Oishi、Takaaki Sato、Noritaka Chida
    DOI:10.1246/bcsj.20210372
    日期:2022.2.15
    chemoselective nucleophilic addition of unsaturated lactone derivatives provides tetracyclic natural products. While stemonine is obtained by an Ir-catalyzed lactam-selective reductive Mannich reaction, saxorumamide and isosaxorumamide are produced through the lactone-selective nucleophilic addition of the lithiated 2-silyl-furan. The developed conditions for the lactam-selective nucleophilic reactions
    我们的研究小组一直在探索一种用于复杂生物碱的简明全合成的内酰胺策略。在本文中,我们报告了基于内酰胺策略的五元环化学选择性组装统一全合成茎酰胺类生物碱的全部细节。首先,通过不饱和γ-内酰胺与不饱和γ-内酯的插藤迈克尔加成-还原序列,实现了三环茎酰胺的简明和克级合成,然后是N-烷基化形成七元环。干酪酰胺作为一种常见的中间体,不饱和内酯衍生物的化学选择性亲核加成提供了四环天然产物。干草碱是通过 Ir 催化的内酰胺选择性还原曼尼希反应获得的,而 saxorumamide 和 isosaxorumamide 则是通过锂化的 2-甲硅烷基呋喃的内酯选择性亲核加成产生的。所开发的内酰胺选择性亲核反应条件非常通用,并且被发现适用于五环茎莨菪碱和异骨莴苣素的全合成。该策略使三环、四环和五环干酰胺类生物碱的简明和统一的全合成能够在 12 个步骤内从市售化合物中获得。
  • Unified Total Synthesis of Stemoamide-Type Alkaloids by Chemoselective Assembly of Five-Membered Building Blocks
    作者:Makoto Yoritate、Yoshito Takahashi、Hayato Tajima、Chisato Ogihara、Takashi Yokoyama、Yasuki Soda、Takeshi Oishi、Takaaki Sato、Noritaka Chida
    DOI:10.1021/jacs.7b10944
    日期:2017.12.20
    A unified total synthesis of stemoamide-type alkaloids is reported. Our synthetic approach features the chemoselective convergent assembly of five-membered building blocks via stemoamide as the common precursor to tetracyclic natural products. The synthesis consists of two successive coupling reactions of the three five-membered building blocks. The first coupling reaction is the vinylogous Michael
    报道了茎酰胺类生物碱的统一全合成。我们的合成方法的特点是通过作为四环天然产物的常见前体的茎酰胺对五元结构单元进行化学选择性聚合组装。该合成由三个五元结构单元的两个连续偶联反应组成。第一个偶联反应是乙烯基迈克尔加成/还原序列,它使茎酰胺的克级合成成为可能。第二个偶联反应是化学选择性亲核加成到茎酰胺。虽然内酯选择性亲核加成到茎酰胺提供了saxorumamide 和isosaxorumamide,但内酰胺选择性还原亲核加成导致了茎氨酸的形成。两种化学选择性亲核加成都能直接修饰茎酰胺,
  • Tailored Synthesis of Skeletally Diverse <i>Stemona</i> Alkaloids through Chemoselective Dyotropic Rearrangements of β‐Lactones
    作者:Zhen Guo、Ruiyang Bao、Yuanhe Li、Yunshan Li、Jingyang Zhang、Yefeng Tang
    DOI:10.1002/anie.202102614
    日期:2021.6.21
    chemoselective dyotropic rearrangements of β-lactones involving alkyl, hydrogen, and aryl migration, respectively. By the rational manipulation of substrate structures and reaction conditions, these dyotropic rearrangements proceeded with excellent efficiency, good chemoselectivity and high stereospecificity. Furthermore, several polycyclic Stemona alkaloids, including saxorumamide, isosaxorumamide, stemonine
    描述了以 β-内酯的定制dyotropic 重排为关键元素的具有骨骼多样性的百部生物碱的集体合成。具体而言,首先通过分别涉及烷基、氢和芳基迁移的 β-内酯的化学选择性dyotropic 重排,获得了与茎酰胺、晚节油环素和帕维司汀相关的三个典型的 5/7/5 三环骨架。通过对底物结构和反应条件的合理控制,这些自致变重排以优异的效率、良好的化学选择性和高立体定向性进行。此外,几种多环百合通过后期衍生化从上述三环骨架中获得生物碱,包括saxorumamide、isosaxorumamide、stemonine和bisdehydroonestemoninine。还开发了一种新型可见光光氧化还原催化的正式 [3+2] 环加成,它为获取氧杂螺丁烯内酯和相关支架提供了宝贵的工具。
  • Kondo; Satomi, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1947, vol. 67, p. 182,183
    作者:Kondo、Satomi
    DOI:——
    日期:——
  • Total Synthesis of (−)-Stemonine
    作者:David R. Williams、Khalida Shamim、Jayachandra P. Reddy、George S. Amato、Stephen M. Shaw
    DOI:10.1021/ol035368q
    日期:2003.9.1
    [reaction: see text] An enantioselective total synthesis of (-)-stemonine (1) is reported via a convergent assembly of the acyclic precursor 2. Key transformations include a Staudinger-aza-Wittig reaction to form the central perhydroazepine ring system and an iodine-induced tandem cyclization to construct the pyrrolidino-butyrolactone framework.
    [反应:见正文]通过无环前体2的会聚组装,报道了对-(-)-stemonine(1)的对映选择性全合成。关键的转化包括Staudinger-aza-Wittig反应形成中央全氢氮杂多环体系和碘诱导的串联环化反应,以构建吡咯烷基-丁内酯框架。
查看更多

同类化合物

金刚大碱 百部碱 新对叶百部碱 对叶百部碱 (7aR,8R,8aS,11S,11aS,11bR,11cR)-8-乙基十二氢-11-甲基-呋喃并[2,3-h]吡咯并[3,2,1-jk][1]苯并氮杂卓-10(2H)-酮 <3'S-<3'α,9'α(S*),9'aα>>-1',2',3',5',6',7',8'-octahydro-4-methyl-5-oxospiropyrrolo<1,2-a>azepin>-3'-carboxylic acid, hydrobromide salt <3'S-<3'α(S*),9'α(S*),9'aα>>-3'-(2,5-dihydro-4-methyl-5-oxo-2-furanyl)-1',2',3',5',6',7',8'-octahydro-4-methylspiropyrrolo<1,2-a>azepin>-5-one stemoamide (2S,4R,3'S,8'R,9a'S,2’’S,4’’S)-8'-methoxy-4-methyl-3’-(4-methyl-5-oxotetrahydrofuran-2-yl)octahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5(4H)-one tuberostemospiroline 2-oxostenine (3aR,10aR,10bR)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione (3aR,9aS,9bR)-3a,6,8,9,9a,9b-Hexahydro-1H-3-oxa-6a-aza-cyclopenta[e]azulene-2,7-dione (2S,3'S,8'R,9a'S)-3'-tert-butyldiphenylsilyloxymethyl-8'-methoxy-1',2',3',7',8',9a'-hexahydro-5H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(6'H)-dione diethyl (2S,3'S,8'R,9a'S)-3'-tert-butyldiphenylsilyloxymethyl-8'-methoxy-5,5'-dioxo-1',2',3',5',6',7,'8',9a'-octahydro-5H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin-4-yl}phosphonate (2S,4R,3'S,8'R,9a'S,2’’S)-8'-methoxy-4-methyl-3’-(4-methylene-5-oxotetrahydrofuran-2-yl)hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (2S,4R,3'S,8'R,9a'S,2’’R)-8'-methoxy-4-methyl-3’-(4-methylene-5-oxotetrahydrofuran-2-yl)hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (1R,2S,10R,12R,16R)-14,14-dimethyl-11,13,15-trioxa-6-azatetracyclo[8.6.0.02,6.012,16]hexadec-8-en-5-one 13-desmethyl-5-oxostenine (3aR,10aS)-1-methyl-3a,4,5,6,10,10a-hexahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(9H)-dione (1R,9R,10R,11S,14S,15S,16R)-14-methyl-10-prop-2-enyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecane-5,13-dione 8-des-ethyl-(8S)-allyl-(-)-tuberostemonine didehydrotuberostemonine (-)-4-thiostenine (-)-4-oxostenine (3aR,10aS,10bS)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione (+)-9a-epi-stemoamide (2S,4R,3'S,8'R,9a'S)-3'-hydroxymethyl-8'-methoxy-4-methylhexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione isoprotostemonine (1S,2S,3R,4R,6R)-3-hydroxy-4-methoxy-5-oxa-10-azatricyclo[8.3.0.02,6]tridecan-11-one (1S,3aR,7S,9aS,9bR)-1-methyl-7-((2S,4S)-4-methyl-5-oxotetrahydrofuran-2-yl)decahydro-3-oxa-6a-azacyclopenta[e]azulen-2-one 4-methoxy-3-methyl-5-[(2Z,3aR)-1t-methyl-8t-((2S)-4c-methyl-5-oxo-tetrahydrofuran-2r-yl)-(3ar,10at,10bt)-decahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepin-2-ylidene]-5H-furan-2-one 8-epi-stemoamide sessilifoliamide A (2R,3'S,8'R,9a'S)-3'-(tert-butyldiphenylsilyloxy)methyl-8'-methoxy-4-methylenehexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin}-5,5'(4H,6'H)-dione (2R,3'S,8'R,9a'S)-8'-methoxy-4-methylene-3'-[(2S)-4-methylene-5-oxotetrahydrofuran-2-yl]hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (2R,3'S,8'R,9a'S)-3'-hydroxymethyl-5,5'-dioxo-8'-methoxy-4-methylenehexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin}-(4H,6'H)-carbaldehyde (2R,3'S,8'R,9a'S,2''R)-8'-methoxy-4-methylene-3'-[(2S)-4-methylene-5-oxotetrahydrofuran-2-yl]hexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepine}-5,5'(4H,6'H)-dione (2R,3'S,8'R,9a'S)-3'-hydroxymethyl-8'-methoxy-4-methylenehexahydro-3H-spiro{furan-2,9'-pyrrolo[1,2-a]azepin}-5,5'(4H,6'H)-dione protostemonine (3S,9R,10R,11S,15R)-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-10-prop-2-enyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadec-6-en-13-one Tuberostemonin (1R,4S,10R,11R,12R,15S,16S)-11-ethyl-15-hydroxy-15-methyl-4-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-13-oxa-5-azatetracyclo[8.6.0.01,5.012,16]hexadecan-14-one (1R,3S,9R,10R,11S,14S,15S,16R)-3-[(2S)-4,4-dimethyl-5-oxooxolan-2-yl]-14-methyl-10-prop-2-enyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecan-13-one (3S,9R,10R,11S,14S,15S,16R)-10-ethyl-14-methyl-3-[(2S,4R)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecan-13-one (1S,2R,3S)-3-methyl-11-[(2S)-4-methyl-5-oxooxolan-2-yl]-5-oxa-10-azatricyclo[8.3.0.02,6]tridecan-4-one (9R,10R,11S,14S,15S,16R)-10-ethyl-14-methyl-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadecan-13-one (10S,11S,14R,15R)-10-ethyl-14-methyl-3-[(2S,4S)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.04,16.011,15]hexadeca-1(16),2-dien-13-one